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Diabetes care in the covid-19 era has changed drastically in order to meet with new demands and
new challenges that the pandemic has brought. This article explains how some new treatment guidelines
may improve patient quality and safety for patients with diabetes. Updated treatment guidelines include
self-management of diabetes in inpatient settings, new glucose target ranges (140-180 mg/dL), and
various new contraindications for medicines that frequently increase blood glucose.
During the time of covid, we have gained a lot of knowledge of how to manage diabetes in the
inpatient setting, especially as it pertains to people who are covid possible. New guidance suggests that
all diabetics should self-manage their own diabetes inpatient that are capable and do not have a
contraindication such as DKA/HHS or any other illness/condition that would hinder their ability to operate
a CGM/Insulin pump. Guidance has been updated to include weight-based insulin calculations as a safe
and effective way of calculating diabetic’s insulin dose. New guidance also suggests that all diabetics on
insulin should be considered for basal as well as correction insulin with an ideal ratio being 50% basal 50%
prandial with corrections as needed. Metformin should be stopped on patients with covid-19 due to risk
of dehydration as well as other medications that can cause glucagon release, or medications that can
result in dehydration.
This study, while relating specifically to adult diabetics with covid-19, suggests that all diabetics
should self-monitor inpatient with a CGM/Insulin pump therapy. The article concludes that using many of
their suggested new guidance’s not only increases safety and efficacy, but also decreases workload for
healthcare workers as well as lowers the risk of hypoglycemic events.
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This Journal contains the entire updated guidelines for diabetes managements from 2022.
This Journal contains all of the treatment and clinical standard practices for healthcare workers as
it pertains to the treatment of diabetes. All types of diabetes are included and mentioned in the
literature. This journal was written and reviewed by the American Diabetes Association, and it’s board
members. Countless physicians rely on this information as a standard of practice.
According to the American Diabetes Association, “Recommendation 7.29 has been modified to
include outpatient procedures and the consideration that people should be allowed continued use of
diabetes devices during inpatient or outpatient procedures when they can safely use them and
supervision is available”
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This article explains how diabetes care has changed during the covid-19 pandemic. The article
explains many different ways in which healthcare workers can limit exposure to infectious diseases in
patients who have diabetes by placing infusion set outside of rooms, storing insulin and other
medications inside of the patient room, and use CGM’s to remotely monitor blood glucose. CGM’s have
shown good results in the inpatient system during covid-19. Despite the fact they are not approved by the
FDA for inpatient use, they have been shown to statistically lower the amount of hypoglycemic events as
well as total patient time spent with hypoglycemia. Clinically, certain medications should be avoided for
diabetics with infectious disease, particularly those that are known to increase blood sugar through
various methods. There are suggestions as well for mitigating the effects of hyperglycemia caused by
these medication such as intensifying insulin
This article explains similar points to other similar articles coming out of the covid-19 pandemic.
The treatment of diabetes has changed quite a bit for all levels of healthcare due to not only the
pandemic, but the furthering of knowledge, skills, and tools that the pandemic has brought us. Certain
drugs, like steroids, should be particularly paid attention to when diabetics are involved in the inpatient
setting. Withholding these types of drugs is not always viable, especially in the presence of infectious
disease. While this may be the case, and more intense management of diabetes is needed for these
patients, CGM’s/ Insulin pumps, and out of room insulin infusion pumps have helped limit patient contact
while also improving or maintaining patient outcomes.

This article speaks strongly to the idea that patients who are capable of self-management of their
own diabetes should be allowed to do so. Guidelines for allowing a patient to self-manage include having
only one glucose monitor per patient, reporting of glycemic events to staff, and insulin dosage reporting
to staff. Another suggestion is to either turn off closed loop systems or having a protocol for avoiding
pump malfunction by avoiding patient/pump exposure to radiation, electromagnetic fields, and certain
medications. Patients should have their devices removed when it is believed that they have deteriorated
enough to no longer be able to self-manage. To that end, all diabetic patients should be reassessed
several times a day to ensure that self-management is safe and effective
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This research study examines the qualitative differences between continuous glucose monitoring
for type one diabetics against manual glucose monitoring. Participants were asked to answer the blood
glucose monitoring system rating questionnaire to measure qualitative differences between the use of
continuous glucose monitors (CGM) and self-monitoring blood glucose (SMBG).
Patients’ responses to questionnaires told researchers that CGMs along with continuous
subcutaneous insulin infusion (CSII) was more beneficial to the patient’s outlook on their own diabetes
care than SMBG. Metrics found that that CGM/SMBG group gave statistically better scores to how they
perceive their own glucose control efficacy, overall health satisfaction, desire to switch to CGM/CSII, as
well as willingness to recommend. At the same, members in the CGM/CSII reported lower interference to
daily living.
This study shows that, at least in the opinions of those who wear the devices, that CGM/CSII is
better than manual control. While this is not the end all be all the argument, we do know that perceived
outlook on one’s own health is an important factor in obtaining good health outcomes for patients of all
types. Better health outcomes are also generally associated with higher quality scores and metrics for
hospitals.

Umpierrez, G. E., & Klonoff, D. C. (2018). Diabetes Technology Update: Use of Insulin Pumps and
Continuous Glucose Monitoring in the Hospital. Diabetes care, 41(8), 1579–1589.
https://doi.org/10.2337/dci18-0002
This literature review examines the use of CGM/CSII in the hospital setting. Using an insulin pump
or CGM in the hospital setting can be difficult and face many barriers. One of the main barriers is
provider/nurse education. Without knowledge of how to work these devices, providers and nurses are
more likely to want to use older established protocols. The reasons for falling back to established
protocols are many, but one of the main ones is confidence in safety. Lack of knowledge is known to lead
to confusion for staff, possible medication errors, and lesser health outcomes for patients.
The biggest problem with this literature review is expressed very early on in the paper: There is
not enough research on the subject matter of CGM/CSII therapy use in hospital setting. CMG/CSII therapy
for inpatient use should be considered only when the patient is alert, orientated, and capable of
managing the system themselves. Other contraindications include DKA as well as mental illness. CMG use
specifically can be for providers, the patient, or both. Little CGM data is available in the United States,
with only the GlucoScout and the OptiScanner 5000 being cleared for use by the FDA. Ultimately, while
some studies do show potential for these types of devices to assist in catching hypo and hyperglycemic
events, studies are small and contradictory for the time being.
This study reinforces the idea clearly that more studies are needed about inpatient use of CGM
and CSII. The idea that diabetics who can do so, should manage their own CGM/CSII systems is an
important note here. The compiled data shows small, but statistically significant improvements on quality
and health outcome scores of diabetics who are allowed to continue their outpatient diabetes regiment
in the hospital, with the caveat that the data is not strong due to small study groups.
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This is a literature review of the current standards of care for diabetes across several medical
associations. These guidelines include all the standards of care for diabetics, type 1 and 2. These
standards of care include various target blood glucose levels, monitoring methods, insulin therapies, as
well as many other aspects of diabetes care.
This article ultimately explains how the various standards of care for diabetics fails to meet
quality expectations. One of the major points of the article is that all diabetes care should be highly
individualized given the different presentations that patients have. Guidelines for when and how to treat
high levels of low-density lipoproteins are debated across many agencies. Metformin remains the gold
standard in 2022 for the treatment of type 2 diabetes, however in Japan it is still not considered a first
line agent. Also, guidelines for when to treat type 2 diabetics with insulin therapy have changed and
debated amongst different agencies from between A1C greater than 9 to A1C greater than 10.
This review does go over many of the benefits of CGM/CSII therapy, as well as mentions that
insulin pump/CGM therapy is the gold standard for type 1 diabetes care. CGM’s are considered so
important to the proper maintenance of type 1 diabetes that new guidance says all type 1 diabetics
should have one. Insulin pumps are also recommended for use in all adult type 1 diabetics that
experience severe hypoglycemia, even in the absence of a CGM.

